Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target

$339.04 -0.62 (-0.18%)

(As of 11/12/2024 ET)

Madrigal Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
1

Hold
2

Buy
10

Based on 13 Wall Street analysts who have issued ratings for Madrigal Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 2 have given a hold rating, and 10 have given a buy rating for MDGL.

Consensus Price Target

$347.33
2.45% Upside

According to the 13 analysts' twelve-month price targets for Madrigal Pharmaceuticals, the average price target is $347.33. The highest price target for MDGL is $441.00, while the lowest price target for MDGL is $150.00. The average price target represents a forecasted upside of 2.45% from the current price of $339.04.

MDGL Analyst Ratings Over Time

Type	Current Forecast 11/14/23 to 11/13/24	1 Month Ago 10/15/23 to 10/14/24	3 Months Ago 8/16/23 to 8/15/24	1 Year Ago 11/14/22 to 11/14/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$347.33	$343.83	$343.83	$313.09
Forecasted Upside	2.45% Upside	59.60% Upside	40.63% Upside	100.10% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

625,000% Gain (Ad)

Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

>> Dive into the Workshop Here

MDGL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Madrigal Pharmaceuticals Stock vs. The Competition

Type	Madrigal Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.69	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	2.45% Upside	25,508.18% Upside	7.92% Upside
News Sentiment Rating	Positive News See Recent MDGL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/5/2024	B. Riley 4 of 5 stars		Boost Target	Neutral ➝ Neutral	$194.00 ➝ $236.00	-28.05%
11/1/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$411.00 ➝ $441.00	+41.45%
10/23/2024	Oppenheimer 3 of 5 stars		Lower Target	Outperform ➝ Outperform	$375.00 ➝ $350.00	+71.91%
10/22/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$390.00 ➝ $390.00	+86.70%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Agrawal Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral
8/8/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$382.00 ➝ $371.00	+54.04%
625,000% Gain (Ad) Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here
8/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$405.00 ➝ $360.00	+53.79%
7/16/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Outperform ➝ Market Outperform	$381.00 ➝ $385.00	+36.85%
6/11/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$382.00	+49.87%
4/22/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Underperform	$150.00	-29.26%
3/15/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$338.00 ➝ $377.00	+30.88%
3/15/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$349.00 ➝ $390.00	+35.40%
3/14/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$336.00	+16.65%
12/20/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$145.00 ➝ $315.00	+25.86%
12/20/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$129.00 ➝ $309.00	+31.58%
12/19/2022	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Market Perform
12/19/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$178.00 ➝ $375.00	+66.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 03:39 AM ET.

MDGL Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Madrigal Pharmaceuticals is $347.33, with a high forecast of $441.00 and a low forecast of $150.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There is currently 1 sell rating, 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares.
: According to analysts, Madrigal Pharmaceuticals's stock has a predicted upside of 2.45% based on their 12-month stock forecasts.
: Madrigal Pharmaceuticals has been rated by research analysts at B. Riley, Cantor Fitzgerald, HC Wainwright, Oppenheimer, and UBS Group in the past 90 days.
: Analysts like Madrigal Pharmaceuticals less than other "medical" companies. The consensus rating score for Madrigal Pharmaceuticals is 2.69 while the average consensus rating score for "medical" companies is 2.80. Learn more on how MDGL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

625,000% Gain (Ad)

>> Dive into the Workshop Here

This page (NASDAQ:MDGL) was last updated on 11/13/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Madrigal Pharmaceuticals (MDGL) Stock Forecast & Price Target